spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

SMiís 9th Annual Biosimilars & Biobetters Conference

SMiís 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018
Copthorne Tara Hotel, London, UK

The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK.

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.

After over a decade, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe.

We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or the originator dominate? Have we done enough to convince the payer, prescriber and patient to switch?

Join us to hear experiences of key opinion leaders and evaluate market access, opportunities and commercialisation strategies with industry-thought experts.

Who should attend?

Chief Executives, Vice Presidents, Executive Directors, Directors, Heads, Managers and Specialists from the following, but not limited to, sectors should attend:

  • Biosimilars / Biologics
  • Biopharmaceuticals
  • Research and Development
  • Legal Affairs
  • Intellectual Property
  • Regulatory Compliance
  • Quality affairs and control
  • Pharmacovigilance, Drug Safety and Risk Management
  • Business Development
  • Commercialisation
  • Marketing and sales

Early bird rates

  • BOOK BY 30TH APRIL AND SAVE £400
  • BOOK BY 31ST MAY AND SAVE £200
  • BOOK BY 29TH JUNE AND SAVE £100

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS

Tuesday 25th September 2018,

Copthorne Tara Hotel, Central London, UK

A: Global Development of Biosimilars: A Refresher

08.30 - 12.30

Workshop Leader: Michel Mikhail, Global Expert in Biosimilars

B: Value Based Agreements with Biosimilars: Architecture of Value Based Agreements

13.30 - 17.30

Workshop Leader: Omar Ali, Visiting Lecturer Value Based Pricing, University of Portsmouth & Former Adviser, NICE

This event is CPD accredited.

#SMiBioSim

phone +44 (0)20 7827 6000
email ssapal@smi-online.co.uk
web bit.ly/2HKQoaq
email Copthorne Tara Hotel, London, UK
 
Print this page
Send to a friend
   
spacer
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

Banner of PHPL West Coast_events_95 on Samedan Banner of Nordics_Events_97 on Samedan

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>


News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement